Sartorius Stedim Biotech (SDMHF) Stock Price, News & Analysis

Company Overview

Sartorius Stedim Biotech SA (OTCMKTS: SDMHF) is a global provider of bioprocessing equipment and services for the biopharmaceutical industry. The company develops and manufactures technologies that support the development and production of vaccines, monoclonal antibodies, therapeutic proteins and cell‐ and gene‐based therapies. Its solutions address both upstream processes—such as cell cultivation and fermentation—and downstream processes, including filtration, centrifugation and chromatography.

Key product offerings include single‐use bioreactors and mixers, modular filtration assemblies, prepacked chromatography columns, and a wide range of cell culture media and buffer systems. The company also supplies laboratory instrumentation for process development, such as cell counting devices, automated liquid handling systems and critical cleaning and sterilization equipment. A focus on single‐use technologies has allowed customers to reduce the risk of contamination, shorten production timelines and enhance operational flexibility.

Founded as part of the Sartorius Group, Sartorius Stedim Biotech traces its roots to the 1870 establishment of Sartorius AG in Germany, with the Stedim Biotech subsidiary later integrated to form a dedicated bioprocess solutions business. Headquartered in Aubagne, France, the company has production and research facilities across Europe, North America and Asia‐Pacific. Its global network of sales and service centers ensures technical support and training for biopharmaceutical manufacturers at every stage of the production lifecycle.

Sartorius Stedim Biotech’s growth strategy emphasizes investment in research and development, strategic acquisitions and expansion of its single‐use portfolio. By collaborating with industry and academic partners, the company aims to drive innovation in bioprocessing, accelerating the delivery of life‐saving therapies to patients worldwide.

Key Stats

• Today's Range: $208.48 to $208.48
• 50-Day Range: $182.07 to $215.50
• 52-Week Range: $178.30 to $264.30
• Volume: 11 shs
• Average Volume: 2,062 shs
• Market Capitalization: N/A
• P/E Ratio: 48.37
• Dividend Yield: 0.58%
• Price Target: N/A
• Consensus Rating: Moderate Buy

Sartorius Stedim Biotech Stock Analysis - MarketRank™

Sartorius Stedim Biotech scored higher than 4% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 1.3 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Sartorius Stedim Biotech has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on no strong buy ratings, 1 buy rating, 1 hold rating, and no sell ratings.

Amount of Analyst Coverage

Sartorius Stedim Biotech has received no research coverage in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Sartorius Stedim Biotech is 48.37, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 45.60.

Price to Earnings Ratio vs. Sector

The P/E ratio of Sartorius Stedim Biotech is 48.37, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 271.26.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Sartorius Stedim Biotech has a short interest ratio ("days to cover") of 522.31, which indicates bearish sentiment.

Change versus previous month

Short interest in Sartorius Stedim Biotech has recently increased by 2.98%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.8 / 5
• Dividend Strength: Weak

Dividend Yield

Sartorius Stedim Biotech has a dividend yield of 0.84%, which is in the bottom 25% of all stocks that pay dividends.

Dividend Growth

Sartorius Stedim Biotech does not have a long track record of dividend growth.

Dividend Coverage

The dividend payout ratio of Sartorius Stedim Biotech is 27.84%. This payout ratio is at a healthy, sustainable level, below 75%.

News and Social Media

• Score: N/A
• News Sentiment: N/A

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Sartorius Stedim Biotech insiders have not sold or bought any company stock.

Percentage Held by Institutions

9.21% of the stock of Sartorius Stedim Biotech is held by institutions.

Company Calendar

• Today: 8/15/2026
• Next Earnings (Estimated): 10/22/2026

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Healthcare
• Industry: Healthcare Equipment & Supplies
• Sub-Industry: N/A
• Current Symbol: OTCMKTS:SDMHF
• CIK: 1794363
• Web: www.sartorius.com
• Phone: (344) 284-5600
• Fax: N/A
• Employees: 10,382
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 48.37
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A